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ABBREVIATIONS 
 
 
AAV   Adeno associated virus 
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Ang   Angiopoietin 
ATP   Adenosine triphosphate 
BEC   Blood vascular endothelial cell 
BM   Basement membrane 
cDNA   Complementary deoxyribonucleic acid 
CAM   Chorioallantoic membrane 
CUB Protein domain: the name originates from the first three proteins the domain was 
found in (Complement subcomponents C1r/C1s, sea urhin EGF-like protein, bone 
morphogenic protein 1) 
DMSO    dimethyl sulfoxide 
E   Embryonic day 
EC   Endothelial cell 
ECM   Extracellular matrix 
EGF   Epidermal growth factor 
FGF   Fibroblast growth factor 
FIGF   c-fos induced growth factor (VEGF-D) 
Flk1   Fetal liver kinase 1 (mouse VEGFR-2) 
Flt1   Fms-like tyrosine kinase 1 (VEGFR-1) 
Flt4   Fms-like tyrosine kinase 4 (VEGFR-3) 
HDMVEC  Human dermal microvascular endothelial cell 
HIF   Hypoxia-inducible factor  
HSPG   Heparan sulphate proteoglycan 
IFP   Interstitional fluid pressure 
Ig   Immunoglobulin 
K14   Keratin-14 
kb   Kilobase 
kDa   Kilodalton 
KDR   Kinase insert domain containing receptor (human VEGFR-2) 
LEC   Lymphatic endothelial cell 
LYVE-1   Lymphatic endothelial hyaluronan receptor 1 
MAPK   Mitogen activated protein kinase 
mRNA   Messenger ribonucleic acid 
NP   Neuropilin 
NRTK   Nonreceptor tyrosine kinase 
P   Postnatal day 
PAE   Porcine aortic endothelial 
PC   Pericyte 
PDGF   Platlet derived growth factor 
PDGFR   PDGF receptor 
PECAM-1  Platelet endothelial adhesion molecule 1 
PlGF   Placenta growth factor 
PTK    Protein tyrosine kinase 
Prox-1   Prospero-related homeobox protein 1  
RTK   Receptor tyrosine kinase 
SLC   Secondary lymphoid chemokine 
SMA   Smooth muscle 〈-actin 
SMC   Smooth muscle cell  
TGF   Transforming growth factor 
VE-cadherin  Vascular endothelial cadherin 
VEGF   Vascular endothelial growth factor 
VEGFR   VEGF receptor 
VPF   Vascular permeability factor (VEGF) 
VRF   VEGF related factor (VEGF-B) 
VRP   VEGF related protein (VEGF-C) 
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ABSTRACT 
 
 
The circulatory system consists of the blood and lymphatic vessels. While blood vessels 
transport oxygen, cells, and nutrients to tissues, the lymphatic vessels collect fluid, cells, and 
plasma proteins from tissues to return back to the blood circulation. Angiogenesis, the 
growth of new blood vessels from pre-existing ones, is an important process involved in 
several physiological conditions such as inflammation, wound healing, and embryonic 
development.  Furthermore, angiogenesis is found in many pathological conditions such as 
atherosclerosis and the growth and differentiation of solid tumors. Many tumor types spread 
via lymphatic vessels to form lymph node metastasis. 
 
The elucidation of the molecular players coordinating development of the vascular system 
has provided an array of tools for further insight of the circulatory system. The discovery of 
the Vascular Endothelial Growth Factor (VEGF) family members and their tyrosine kinase 
receptors (VEGFRs) has facilitated the understanding of the vasculature in different 
physiological and pathological situations. The VEGFRs are expressed on endothelial cells 
and mediate the growth and maintenance of both the blood and lymphatic vasculatures.  
 
This study was undertaken to address the role of VEGFR-2 specific signaling in maturation 
of blood vessels during neoangiogenesis and in lymphangiogenesis. We also wanted to 
differentiate between VEGFR-2 and VEGFR-3 specific signaling in lymphangiogenesis. We 
found that specific VEGFR-2 stimulation alone by gene therapeutic methods is not sufficient 
for production of mature blood vessels. However, VEGFR-2 stimulation in combination with 
expression of platelet-derived growth factor D (PDGF-D), a recently identified member of 
the PDGF growth factor family, was capable of stabilizing these newly formed vessels. 
 
Signaling through VEGFR-3 is crucial during developmental lymphangiogenesis, but we 
showed that the lymphatic vasculature becomes independent of VEGFR-3 signaling after the 
postnatal period. We also found that VEGFR-2 specific stimulation cannot rescue the loss of 
lymphatic vessels when VEGFR-3 signaling is blocked and that VEGFR-2 specific signals 
promote lymphatic vessel enlargement, but are not involved in vessel sprouting to generate 
new lymphatic vessels in vivo, in contrast to the VEGFR-2 dependent sprouting observed in 
blood vessels. In addition, we compared the inhibitory effects of a small molecular tyrosine 
kinase inhibitor of VEGFR-2 vs. VEGFR-3 specific signaling in vitro and in vivo. Our 
results showed that the tyrosine kinase inhibitor could equally affect physiological and 
pathological processes dependent on VEGFR-2 and VEGFR-3 driven angiogenesis or 
lymphangiogenesis. 
 
These results provide new insights into the VEGFR specific pathways required for pre- and 
postnatal angiogenesis as well as lymphangiogenesis, which could provide important targets 
and therapies for treatment of diseases characterized by abnormal angiogenesis or 
lymphangiogenesis. 
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REVIEW OF THE LITTERATURE 
 
 
1. THE CARDIOVASCULAR SYSTEM 
 
The blood vascular system 
 
The cardiovascular system includes the heart and the blood vessels. Arteries deliver 
oxygenated blood to the capillaries where two-way exchange occurs between the blood and 
tissues. Veins collect deoxygenated blood from the microvasculature and carry it back to the 
heart.  
 
Blood vessels consist of a monolayer of blood vascular endothelial cells (BECs) with 
molecular junctions tightly attaching the endothelial cells (ECs) to each other. These 
junctions form barriers, which regulate vessel permeability and the exchange of molecules 
between nearby ECs (reviewed in Dejana, 2004). The blood vessels rest on a basement 
membrane (BM), a thin sheet of extracellular matrix (ECM) composed of collagens, 
laminins, fibronectin, and heparan sulphate proteoglycans (HSPGs), which can vary 
depending on vessel type and tissue environment. Correct assembly of the BM is needed for 
vessel stability, as well as EC morphogenesis and vessel maturation (reviewed in Davis and 
Senger, 2005). In capillaries, the BM is shared by ECs and pericytes (PCs), which actively 
interact with each other and further support and stabilize the vessels. The larger vessels 
regulate blood pressure and transport blood to the capillaries. Layers of vascular smooth 
muscle cells (vSMCs), elastic fibers, and connective tissue surround the vessels making them 
resist high pressure.   
 
Development of the blood vascular system 
 
The blood vascular system is one of the first functional organ systems of the vertebrate 
embryo, and the creation of an accurately patterned network of blood vessels is essential for 
embryonic survival. Vasculogenesis initiates when the common precursor cells of both 
endothelial and blood cells, the hemangioblasts, form aggregates termed blood islands, in 
which the inner cells develop into hematopoietic precursors and the outer population into 
endothelial progenitor cells or angioblasts. Following commitment to the endothelial cell 
lineage, angioblasts may migrate extensively before assembling into a primitive vascular 
plexus of veins and arteries (reviewed in Carmeliet, 2000).  
 
After formation of the primary vascular plexus, new capillaries are generated from the pre-
existing vessels in a process termed angiogenesis. In developmental angiogenesis, new 
vessels are formed either by endothelial sprouting and elongation from pre-existing vessels, 
or by splitting or merging of the pre-existing vessels (reviewed in Lawson and Weinstein, 
2002). After the onset of blood circulation, the emerging vascular plexus is rapidly 
remodelled to resemble a mature system with a hierarchy of large and small vessels.  A large 
amount of different endogenous inducers and inhibitors of angiogenesis have been identified. 
These factors must be tightly controlled and in balance for physiological angiogenesis to 
occur properly. The maturation of blood vessels includes the deposition of the BM and 
recruitment and organization vascular mural cells (reviewed in Carmeliet, 2000). 
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Endothelial and vascular mural cells 
 
Depending on the vessel type, ECs vary in their morphology, function, and gene-expression 
profiles. Morphologically, they differ in size, shape, thickness, number of microvilli, and the 
position of the nucleus. Blood and lymphatic vascular endothelial cells (BECs and LECs) 
represent two distinct cell populations (Hirakawa et al., 2003; Kriehuber et al., 2001; 
Makinen et al., 2001b; Podgrabinska et al., 2002). ECs in tumor vessels are abnormally 
shaped, overlap each other and are only loosely interconnected with openings between the 
cells (Hashizume, 2000). ECs express specific markers that are very helpful in identifying 
these cells in vitro and in vivo. Most of the markers are present on both ECs and 
hematopoietic precursors or mature blood cells, strengthening the idea of a common 
embryonic precursor (Risau, 1995). Some of the endothelial markers are constitutive and 
present in essentially all types of endothelium. Other molecules are expressed only after 
activation by inflammatory cytokines or growth factors (Reviewed in Garlanda and Dejana, 
1997). 
 
Vascular mural cells, pericytes (PC) and vascular smooth muscle cells (vSMCs), are a 
heterogenous group of cells, which stabilize the newly formed vessel wall together with BM 
deposition. vSMCs of large blood vessels are separated from the vascular BM by a layer of 
mesenchymal cells and extracellular matrix. In these vessels, the vSMCs make up a separate 
layer in the vascular wall. PCs are embedded in the endothelial BM and make close contacts 
with the EC. While the role of vSMCs is to mediate vascular contraction and strength, the 
PCs seem to facilitate and integrate cell-to-cell communication. A single PC is often in 
contact with several ECs and therefore suggested to be involved in neighboring EC 
stabilization, contacts, and signaling. The vascular mural cells can be distinguished from the 
ECs by specific marker proteins  (reviewed in Armulik et al., 2005).  
 
Vascular mural cells originate from multiple sources including mesenchymal cells, neural 
crest cells, and epicardial cells (Hungerford and Little, 1999). In embryonic mesodermal 
cells they have common progenitors with the ECs (Flk-1 positive embryonic stem cells), 
which can differentiate into ECs in the presence of vascular endothelial growth factor 
(VEGF) or into vSMCs in the presence of platelet–derived growth factor B (PDGF-B) 
(Yamashita et al., 2000). 
 
Combinations of antiendothelial and antipericyte agents have been shown to have a 
synergistic effect in antiangiogenic therapy for diseases such as cancer and diabetic 
retinopathy (reviewed in Armulik et al., 2005). A combination of growth factors promoting 
both angiogenesis and PC recruitment has also shown to be synergistically effective in 
proangiogenic therapy.  
 
Physiological angiogenesis 
 
Usually ECs of adult, mature, quiescent vessels have a very low proliferating rate. However, 
new vessel growth occurs during some physiological events, such as in female reproductive 
organs (reviewed in Ferrara and Kerbel, 2005). In the adult, angiogenesis appears to be the 
primary mechanism of new vessel formation, although recent studies have suggested that 
bone marrow-derived endothelial precursor cells can be recruited and incorporated into sites 
of active neovascularization (Hristov et al., 2003). 
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Angiogenesis is initiated by an increase in vascular vasodilation and permeability in response 
to angiogenic growth factors. Periendothelial support cells detach and interendothelial 
connections loosen. Once ECs are activated, they start to produce proteases which 
decompose the BM and release factors from the ECM, such as basic fibroblast growth factor 
(bFGF), VEGF, and insulin-like growth factor-1 (reviewed in Carmeliet, 2000). Monocytes 
and macrophages are also recruited to the site of angiogenesis where they secrete growth 
factors (Conway et al., 2001). The growth factors futher stimulate ECs to migrate into the 
tissue, to proliferate, and differentiate to form new vessels. Finally, the ECs start to produce 
PDGF-B to attract PCs and vSMCs to stabilize the newly formed vessels (Lindahl et al., 
1998).  
 
Pathological blood vessel growth 
 
A wide range of diseases, including chronic inflammatory diseases, diabetic retinopathy, 
rheumatoid arthritis, preeclampsia, and cancer are characterized by abnormal angiogenesis. 
In contrast to physiological angiogenesis, pathological angiogenesis is often induced by 
inflammation. Monocytes and macrophages, platelets, mast cells and other leukocytes are 
attracted to sites of inflammation, in part by angiogenic factors such as VEGF (reviewed in 
Takahashi and Shibuya, 2005).  
 
Tumor angiogenesis 
 
Mammalian cells need oxygen and nutrients for survival and therefore have to be located 
within the diffusion limit of oxygen from blood vessels. In order to grow to a size beyond a 
few cubic millimeters, solid tumors must promote new blood vessel growth. Tumor vessels 
develop by sprouting or intussusception from pre-existing vessels. Also, circulating 
endothelial precursor cells from the bone marrow may contribute to tumor angiogenesis 
(Lyden et al., 2001).  
 
Tumor vessels are not always formed only by ECs; rather they can be composed of only 
cancer cells or consist of a mosaic of cancer cells and ECs (Jain, 1988). Tumor vessels are 
structurally and functionally abnormal. They are dilated and tortuous, have an uneven 
diameter, and have excessive branching points, probably due to an imbalance of the 
angiogenic factors (reviewed in Carmeliet and Jain, 2000). Tumor vessel blood flow is 
variable and the vessels are very leaky (Dvorak et al., 1999; Hashizume, 2000). Also, tumor 
vessels may either lack PCs or be covered by abnormal PCs (Morikawa et al., 2002). Tumor 
vessels have also been proposed to express surface proteins that are absent or scarcely 
detectable in normal mature vessels (Huang et al., 1997). 
 
Therapeutic angiogenesis 
 
Therapeutic angiogenesis (promoting new vessel growth to treat ischaemic disorders) has 
been shown to be effective in a variety of animal models of coronary or limb ischemia. 
Clinical trials using the angiogenic factors VEGF or FGF have unfortunately not yielded in 
convincingly positive results (reviewed in Simons, 2005). Recently, studies have shown that 
therapy using hypoxia inducible factor-1 (HIF-1) which promotes expression of growth 
factors both for vessel growth and maturation would be more potent than using single 
angiogenic factors (Heinl-Green et al., 2005; Pajusola et al., 2005). 
 
Already in 1971, it was proposed that tumor growth and metastasis are angiogenesis-
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dependent, and hence, blocking angiogenesis could be a strategy to arrest tumor growth 
(reviewed in Folkman et al., 2000). Several promising strategies to inhibit tumor 
angiogenesis have been designed and tested in vitro and in animal models. These include 
inhibitors that interfere with angiogenic ligands, their receptors or downstream signaling, 
endogenous inhibitors of angiogenesis, or directly targeting of molecules that are specifically 
expressed on the tumor vasculature (Arap et al., 2002). However, only a few of these have 
had any effect in the clinics, despite extensive trials (reviewed Jain et al., 2006). So far, three 
drugs which interfere with VEGF have been approved by Federal Drug Administration 
(FDA) in the USA: Bevacizumab (AvastinTM) is a neutralizing antibody for VEGF which 
was shown to improve the efficacy of chemotherapy in colorectal cancer (Hurwitz, 2004; 
Hurwitz et al., 2004); Pegaptanib (MacugenTM), an oligonucleotide that binds VEGF; and 
Ranibizumab (LucentisTM), an antibody that binds VEGF. The latter two are both used for 
treatment of age-related macular degeneration (AMD) (Gaudreault et al., 2005; Gragoudas et 
al., 2004).  
 
 
2. THE LYMPHATIC SYSTEM 
 
The main function of the lymphatic system is to maintain tissue fluid balance by returning 
interstitial fluid to the venous circulation via the larger lymphatic collecting vessels and the 
thoracic duct. The lymphatic system also has an important role in the immune system and in 
absorption and transportation of digested fats from the intestine (reviewed in Karpanen and 
Makinen, 2006). 
 
The lymphatic system is composed of a vascular network of thin-walled, blind-ended 
capillaries that drain protein-rich lymph from the extracellular spaces within most organs. 
The lymphatic capillaries are valveless endothelial single-cell layer tubes, which have an 
irregular basement membrane, overlapping EC junctions, and they lack PCs and SMCs, 
making them highly permeable to large macromolecules. Collecting lymphatic vessels have 
sparse SMC coverage, which helps moving lymph forward, and valves, which prevent 
backflow (reviewed in Karpanen and Makinen, 2006). Anchoring filaments attach the 
lymphatic vessels to the surrounding tissue.  In addition to the lympahtic vessels, the 
lympahtic system includes lymphoid organs such as the lymph nodes, tonsils, Peyer’s 
patches, spleen, and thymus, all of which play an important role in immune responses. 
Lymphatic vessels are normally not present in avascular structures such as epidermis, 
cartilage and cornea, or in some vascularized organs such as brain, retina and bone marrow 
(reviewed in Oliver and Detmar, 2002). 
 
Development of the lymphatic vessels 
 
During embryogenesis, the development of lymphatic vessels begins after the establishment 
of the blood vasculature when a subset of venous ECs becomes committed to the lymphatic 
endothelial cell lineage. These cells sprout from the major veins in the jugular and 
perimesonephric areas to form primitive lymphatic sacs, from which lymphatic vessels then 
spread by endothelial sprouting to the periphery of the embryo (reviewed in Wigle and 
Oliver, 1999). The homeodomain transcription factor Prox-1 (prospero-related homeobox 
protein 1) has been identified as a critical regulator of lymphatic endothelial cell (LEC) 
differentiation (reviewed in Oliver and Detmar, 2002). Induction of polarized expression of 
Prox-1 in the cardinal vein leads to upregulation of lymphatic-specific genes. The 
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simultaneous expression of the lymphatic-specific genes LYVE-1, Prox-1, VEGFR-3, and 
SLC may lead to irreversible specification of the lymphatic pathway (Wigle et al., 2002). 
 
Physiological and pathological lymphangiogenesis 
 
In the adult, the growth of lymphatic vessels follows the growth of blood vessels, similar to 
the situation occurring in embryonic development. During wound healing, the growth of 
lymphatic vessels lags behind that of blood vessels, and shortly after their formation, 
lymphatic vessels tend to regress (Paavonen et al., 2000). Lymphangiogenesis is not detected 
in chronic wounds, suggesting disturbed VEGFR-3 signaling in an abnormal wound healing 
process, which might be further impaired by the lack of lymphatic vessels. 
Lymphangiogenesis is thus probably an essential feature of tissue repair and inflammatory 
reactions in most organs.  
 
Tumor lymphangiogenesis and lymphatic metastasis 
 
In most human cancers, the lymphatic system serves as the primary route for the metastatic 
spread of tumor cells, and metastasis to the regional lymph nodes is one of the most 
important indicators of tumor aggressiveness (reviewed in Stacker et al., 2002a). VEGF-C 
and -D promote tumor lymphangiogenesis and the metastatic spread of tumor cells (reviewed 
in Saharinen et al., 2004). 
 
Intratumoral lymphatic vessels and metastasis to lymph nodes and lungs have been 
documented in tumor xenografts expressing VEGF-C or VEGF-D (Skobe et al., 2001a; 
Skobe et al., 2001b; Stacker et al., 2001), as well as in VEGF-C or -D transgenic mouse 
tumors  (Mandriota et al., 2001; Von Marschall et al., 2005). VEGF-C-induced tumor 
growth, lymphangiogenesis and lymphatic metastasis were inhibited by adenoviral 
expression of a soluble VEGFR-3-Ig fusion protein, which “traps” available VEGF-C and 
VEGF-D (He et al., 2002; Karpanen et al., 2001). Tumor lymphatic vessels have distinct 
molecular expression patterns from normal LECs (Laakkonen et al., 2002). Therefore, drugs 
specifically targeted to peritumoral lymphatic vessels might inhibit lymphatic metastasis. 
However, destruction of these vessels would further elevate the high interstitial pressure 
inside the tumor, which is known to interfere with the delivery of anti-cancer drugs (Jain and 
Padera, 2002). 
  
Lymphedema 
 
Lymphedema is caused by insufficient lymph transport by lymphatic vessels, which results 
in build-up of protein rich fluid in tissues causing chronic swelling of the extremities (Witte 
et al., 2001). Lymphedema is generally divided into two main categories. Primary 
lymphedema is a rare developmental disorder, characterized by hypoplasia or hyperplasia of 
the cutaneous lymphatic vessels. Kinase inactivating mutations in the VEGFR-3 gene were 
identified in several cases of hereditary, early-onset lymphedema (Milroy disease) (Ferrell et 
al., 1998; Irrthum et al., 2000; Karkkainen et al., 2000). Mutations in the transcription factors 
FoxC2 and Sox18 were also linked to lymphedema-distichiasis and hypotrichosis-
lymphedema-telangiectasia, respectively (Fang et al., 2000; Finegold et al., 2001; Irrthum et 
al., 2003). Secondary lymphedema is caused by damage of the lymphatic vessels due to 
infection, surgery, or trauma. Secondary lymphedema can develop as the result of 
inflammatory obstruction of the draining lymphatic vessels or, for example, after breast 
cancer surgery (reviewed in Rockson, 2000). The most common cause of secondary 
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lymphedema is filariasis caused by the parasitic Wucheriya bancroftii or Brugia malayi with 
a prevalence of over 120 million cases worldwide.  
 
 
Inflammation and wound healing 
 
Edema occurs in inflammatory diseases when the speed of plasma leakage from blood 
vessels exceeds the drainage through lymphatic vessels. Inflammatory cells express VEGFRs 
and are therefore attracted by angiogenic and lymphangiogenic signals. Macrophages secrete 
VEGF, VEGF-C and VEGF-D and can therefore stimulate lymphangiogenesis (Cursiefen et 
al., 2004; Mimura et al., 2001; Schoppmann et al., 2002; Skobe et al., 2001a). These cells 
can also transdifferentiate into LECs, which can incorporate into the lymphatic endothelium 
(Kerjaschki, 2005; Maruyama et al., 2005). Chronic airway inlammation by Mycoplasma 
pulmonis resulted in massive lymphangiogenesis induced by VEGF-C and VEGF-D 
producing inflammatory cells. Whereas the newly formed blood vessels regressed after 
antibiotic treatment, the lymphatic vessels stayed intact much longer (Baluk et al., 2005). 
Proliferation of lymphatic vessels has also been reported in rejected kidney transplants and in 
cornea models of inflammatory neovascularization (Chen et al., 2004; Kerjaschki et al., 
2006). 
 
Therapeutic lymphangiogenesis 
 
Currently, therapeutic options for the management of lymphedema are limited, consisting 
primarily of physiotherapy, massage, and external compression (Witte et al., 2001). The 
discovery of specific genes involved in the regulation of lympahtic vessels and in the 
pathology of lymphedema has lead to experimental approaches for treating lymphedema. 
Adenoviral VEGF-C gene transfer into the skin was shown to result in a strong 
lymphangiogenic response (Enholm et al., 2001), and viral VEGF-C gene therapy induced 
the growth of functional lymphatic vessels in the skin of a mouse model for hereditary 
lymphedema (Karkkainen et al., 2001). However, high levels of VEGF-C also led to blood 
vascular effects such as increased vessel leakiness, presumably through the interaction of 
VEGF-C with VEGFR-2 expressed on the blood vascular endothelium (Saaristo et al., 
2002a). 
 
Adenoassociated virus (AAV)-mediated VEGF-C156S and VEGF-C gene transfer in the 
skin of lymphedema mice induced the formation of functional lymphatic vessels that 
persisted for at least eight months (Saaristo et al., 2002b). VEGF-C lymphangiogenic gene 
therapy has been shown to accelerate diabetic wound healing by inducing persistent 
angiogenesis and lymphangiogenesis (Saaristo et al., 2006). VEGF-C and VEGF-C156S 
lymphangiogenic gene therapy was used to reconstruct the lymphatic vessel network severed 
by the incision wound in free flap operations in an animal model (Saaristo et al., 2004). 
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Figure 1. Schematic structure of blood and lymphatic vessels. Blood vessels consist of a 
monolayer of blood vascular endothelial cells (BECs), which form tight and adherent 
juntions. Vascular mural cells, pericytes (PCs), and vascular smooth muscle cells (vSMCs) 
surround the BECs. The BECs and PCs share a basement membrane (BM), which is needed 
for vessel stability. The lymphatic capillaries are valveless, single endothelial cell layer tubes 
with overlapping lymphatic endothelial cell (LEC) junctions and lacking PCs, making them 
highly permeable to large macromolecules. Anchoring filaments attach the lymphatic 
capillaries to the surrounding tissue. Collecting lymphatic vessels have sparse vSMC 
coverage, which helps move lymph forward, and valves, which prevent backflow. 
 
 
3. CELL-TO-CELL SIGNALING AND PROTEIN PHOSPHORYLATION 
 
The growth and survival of multicellular organisms is a complex process, which therefore 
must be strictly regulated. The synchronized differentiation of cells into different organs is 
largely dependent on the capability of the cells to react to extracellular stimulus and the 
ability to communicate with other cells. Signaling between cells occurs either locally as a 
result of direct contact between cells, or as a result of secreted signal mediators. These signal 
mediators can either be locally acting secreted growth factors or cytokines, or systematically 
circulating endocrine hormones, which mediate signals at their target tissue. Secreted growth 
factors bind to their receptors on the cell surface, which leads to an activation of intracellular 
signaling cascades. The final purpose for this activation is often regulation of different 
transcription factors and therefore reprogramming of the gene expression of the cell.  
 
The key mechanism for intracellular signal transduction is covalent modification of proteins 
through reversible phosphorylation by protein kinases. Growth factor receptors have been 
characterized to be essential regulators of cellular functions. The receptors transmit the 
extracellular signals into the cell and regulate the important cellular processes such as cell 
migration and survival. Many intracellular signaling molecules contribute to a number of 
different signaling cascades. How the cell reacts to a specific stimulation is dependent on the 
length and strength of the signal, the cell type specific expression of receptors and modifying 
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proteins, and the availability of ligands (reviewed in Lowes et al., 2002). Many important 
cellular signals for growth, differentiation, adhesion, migration and apoptosis are transmitted 
by tyrosine phosphorylation of signaling modulators.  
 
Protein tyrosine kinases 
 
Protein tyrosine phosphorylation is the most common mechanism for signaling through 
membranes, mediated principally by all types of transmembrane receptors (reviewed in 
Hunter, 2000). The phosphorylation is carried out by protein tyrosine kinases (PTKs), which 
are divided into receptor tyrosine kinases (RTKs) and nonreceptor tyrosine kinases (NRTKs, 
also called cytoplasmic or intracellular tyrosine kinases). Over 90 PTKs have so far been 
identified in the human genome. These enzymes catalyze the transfer of the gamma 
phosphate of adenosine triphosphate (ATP) to tyrosine residues on protein substrates 
(reviewed in Blume-Jensen and Hunter, 2001; Hubbard and Till, 2000).  
 
The kinase domain in protein tyrosine kinases consists of about 300 amino acids. The three 
dimensional structure of the kinase domain is very well conserved and composed of two 
lobes. The N-terminal lobe is comprised of a five-stranded β-sheet and one α-helix, αC, 
which functions in the regulation of the kinase. The C-terminal lobe is primarily α-helical 
and responsible for binding of the substrate. The linker region between the N- and C-
terminal lobes forms a cleft at the ATP binding site (reviewed in Hubbard and Till, 2000).   
 
Phosphorylation of tyrosine residues in the activation loop (A-loop), located in the C-
terminal lobe of the kinase domain, typically leads to conformational changes and an 
increase in enzymatic activity. This regulation occurs either via trans-autophosphorylation or 
via phosphorylation by different NRTKs (reviewed in Huse and Kuriyan, 2002). 
 
Ligand binding to RTKs induces receptor dimerization and activation, apparently by causing 
a conformational change of the receptor chains. As a result, the receptor becomes 
transphosphorylated on regulatory tyrosines in the activation loop, and promotes 
phosphorylation of target protein tyrosines (reviewed in Jiang and Hunter, 1999). The 
phosphorylated tyrosine residues on the activated receptor serve as docking sites for proteins 
containing phosphotyrosine recognition domains such as PTKs, PTPases, adaptors, scaffolds, 
small GTPase signaling proteins, phospholipid signaling proteins, cytoskeletal regulation 
proteins, transcription factors, etc. These proteins convert extracellular stimuli to a biological 
response through intracellular signaling pathways leading to changes in cellular functions.  
 
 
4. THE VASCULAR ENDOTHELIAL GROWTH FACTORS AND THEIR 
RECEPTORS  
 
The growth and differentiation of blood vascular as well as lymphatic endothelial cells are 
highly complicated and coordinated processes that involve many different growth factors and 
their receptor systems, such as members of the angiopoietin (Ang), ephrin, PDGF, and 
transforming growth factor-β (TGF-β) families (Carmeliet, 2003; Jain, 2003; Yancopoulos et 
al., 2000). However, signaling mediated through the vascular endothelial growth factors 
(VEGFs) and associated receptor systems often represents the major rate-limiting step in 
developmental and physiological angiogenesis. The human VEGF family currently includes 
five members: VEGF, placenta growth factor (PlGF), VEGF-B, VEGF-C, and VEGF-D. 
Recently, two non-human growth factors, orf virus VEGF (also called VEGF-E) and snake 
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venom VEGF (also called VEGF-F) have been added to the family. The VEGFs are secreted, 
dimeric glycoproteins, which all contain characteristic, regularly spaced eight cysteine 
residues, which compose the so-called cystine knot motif. Disulfide bonds covalently link 
the subunits together. 
 
The VEGFs mediate their signals via three receptor tyrosine kinases, VEGFR-1, VEGFR-2, 
and VEGFR-3. The VEGFRs demonstrate structural and functional similarities to the platelet 
derived growth factor (PDGF) receptor family, and form a subfamily within that receptor 
class. All VEGFRs have seven immunoglobulin (Ig) homology domains in the extracellular 
ligand binding part, a transmembrane part, and an intracellular tyrosine kinase domain. Like 
other RTKs, the VEGFRs dimerize and undergo trans-autophosphorylation upon ligand 
binding.  
 
 
 
Figure 2. Receptor binding of VEGF family members to the VEGFRs.  
 
 
VEGF 
 
VEGF, also referred to as vascular permeability factor (VPF) is a major regulator of both 
physiological and pathological angiogenesis, as well as vascular permeability (reviewed in 
Ferrara, 1999b). Human VEGF exist in eight different protein isoforms, having subunit 
polypeptides of 121, 145, 148, 162, 165, 183, 189, and 206 amino acid residues (reviewed in 
Takahashi and Shibuya, 2005). The mouse isoforms are one amino acid residue shorter. 
VEGF is a ligand for the VEGF receptors (VEGFR)-1 and -2. In addition, VEGF165 also 
binds neuropilin-1 (NP-1). The different isoforms differ in their bioavailability: whereas 
VEGF121 is freely soluble and does not bind heparin, the larger isoforms contain increasingly 
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basic and heparin binding C-terminal domains. The major portion of secreted VEGF165 
remains bound to the cell surface and ECM, and VEGF189 and VEGF206 are almost 
completely bound in the ECM (Lee et al., 2005; Park et al., 1993). The longer isoforms can 
be released by proteolytic cleavage, thus increasing local VEGF concentrations during tissue 
growth and remodeling.  
 
VEGF has a wide expression pattern and is produced by a variety of cell types (Ferrara, 
1999a). VEGF expression is critical for the earliest stages of vasculogenesis, as blood 
islands, ECs, and major vessel tubes fail to develop in VEGF knockout embryos. Even loss 
of a single VEGF allele leads to embryonic lethality, indicating a strict dose-dependence for 
VEGF during development (Carmeliet et al., 1996; Ferrara et al., 1996).  
 
VEGF induces angiogenesis by stimulating EC proliferation, migration and survival (Alon et 
al., 1995; Benjamin et al., 1999). Gene expression of VEGF is regulated by a variety of 
stimuli such as growth factors and cytokines as well as by hypoxia, transformation, p53 
mutation and nitric oxide (NO) (reviewed in Takahashi and Shibuya, 2005).  
 
PlGF 
 
Human PlGF has been described in four isoforms PlGF-1, PlGF-2, PlGF-3, and PlGF-4 
(Hauser and Weich, 1993; Maglione et al., 1991; Maglione et al., 1993). PlGF-2 and PlGF-4 
bind heparin via a basic peptide insert near its C-terminus whereas PlGF-1 and PlGF-3 are 
non-heparin binding. PlGF homodimers bind only to VEGFR-1 (Park et al., 1994), but 
heterodimers of PlGF-1 and VEGF165 have been characterized, which also can bind to 
soluble VEGFR-2 (Cao et al., 1996; DiSalvo et al., 1995; Park et al., 1994). PlGF-2 also 
binds NP-1 and -2 (reviewed in Takahashi and Shibuya, 2005). Overexpression of PlGF has 
been reported to induce increased vascularization and vessel permeability in vivo and shown 
to be mitogenic and chemotactic for ECs in vitro (Odorisio et al., 2002; Ziche et al., 1997). 
Loss of PlGF did not affect vasculogenesis or developmental angiogenesis, but resulted in 
impaired pathological angiogenesis during ischemia, inflammation, wound healing, and 
cancer (Carmeliet et al., 2001).  
 
VEGF-B 
 
VEGF-B, also referred as VEGF related factor (VRF), exists as two isoforms, VEGF-B167 
and VEGF-B186, and it can form heterodimers with VEGF (Olofsson et al., 1996a; Olofsson 
et al., 1996b). VEGF-B is a ligand for VEGFR-1 and NP-1 (Makinen et al., 1999; Olofsson 
et al., 1998). Both forms of VEGF-B are broadly expressed, being most abundant in heart 
and skeletal muscle (Aase et al., 1999; Olofsson et al., 1996a). Deletion of the VEGF-B gene 
did not have a vascular effect, but resulted in abnormal cardiac development and function 
(Aase et al., 2001; Bellomo et al., 2000).  
 
VEGF-C and VEGF-D 
 
VEGF-C, also referred to as VEGF-related protein (VRP), and VEGF-D, also referred to as 
c-Fos-induced growth factor (FIGF), are the primarly lymphangiogenic factors (Achen et al., 
1998; Joukov et al., 1996; Lee et al., 1996; Veikkola et al., 2001). No splicing variants have 
been reported in humans, while two isoforms of VEGF-D, VEGF-D358 and VEGF-D326, have 
been identified in mouse (Baldwin et al., 2001). VEGF-C and VEGF-D have precursor 
proteins with both N- and C-terminal propeptides flanking the VEGF homology region. They 
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are converted into mature forms by specific cleavage enzymes via two proteolytic steps 
(Joukov et al., 1997; McColl et al., 2003; Siegfried et al., 2003; Stacker et al., 1999). Upon 
proteolytic cleavage the affinity of VEGF-C and VEGF-D towards VEGFR-3 increases and 
the fully processed, mature forms also binds to and activates VEGFR-2. Interestingly, the 
mouse VEGF-D is a specific ligand of VEGFR-3, unable to bind VEGFR-2 (Baldwin et al., 
2001).  VEGF-C and VEGF-D are also able to bind NP-1 and NP-2 (Karpanen et al., 2006). 
Deletion of the VEGF-C gene in mice shows that VEGF-C is required for the initial steps in 
lymphatic development (Karkkainen et al., 2004), whereas VEGF-D-deficient mice are 
healthy and display no pathologic changes consistent with a defect in lymphatic function 
(Baldwin et al., 2005). Even though both VEGF-C and VEGF-D induce EC proliferation and 
migration in vitro (Achen et al., 1998; Joukov et al., 1996; Lee et al., 1996; Makinen et al., 
2001b), only VEGF-C induces vascular permeability (Joukov et al., 1997; Stacker et al., 
1999).  
 
VEGF-C is most abundant in the heart and lung and is expressed mainly by mesenchymal 
cells and vascular SMCs (Karkkainen et al., 2004; Kukk et al., 1996). VEGF-D has a broader 
expression pattern, in the lung, heart, skeletal muscle, colon, and small intestine (Achen et 
al., 1998). VEGF-C acts as a highly specific lymphangiogenic factor in the mature 
chorioallantoic membrane (CAM) and in the skin of transgenic mice (Jeltsch et al., 1997; Oh 
et al., 1997). However, recombinant VEGF-C also promotes angiogenesis when applied to 
early CAM where lymphatic vessels have not yet developed, to avascular mouse cornea, to 
mouse cornea or to rabbit ischemic hindlimb (Cao et al., 1998; Rissanen et al., 2003; 
Witzenbichler et al., 1998). In both zebrafish and in Xenopus tadpoles, VEGF-C is required 
for angiogenesis (Ny et al., 2005; Ober et al., 2004). VEGF-D has been reported to promote 
angiogenesis in rabbit cornea and muscle, but in other systems, such as mouse skin, VEGF-D 
induces exclusively lymphangiogenesis (Marconcini et al., 1999; Rissanen et al., 2003; 
Veikkola et al., 2001). 
 
Orf virus VEGFs and snake venom VEGF 
 
Genes with sequence homology to VEGF have been discovered in Orf viruses and in 
pseudocowpox viruses. These virus-encoded VEGFs, commonly named VEGF-E, cause 
highly vascularized and pustular dermatitis in sheep, goats, and occasionally in humans 
(Lyttle et al., 1994; Meyer et al., 1999; Ogawa et al., 1998). The virus-encoded VEGFs can 
be separated into two groups, with VEGF-ED1701 and VEGF-ENZ2 most closely related to 
VEGF and PlGF, while VEGF-ENZ7 is similar to VEGF-C and VEGF-D (Holmes and 
Zachary, 2005). The virus-encoded VEGFs bind to VEGFR-2 and induce its 
autophosphorylation to almost the same extent as VEGF, but do not bind to VEGFR-1 
(Meyer et al., 1999; Ogawa et al., 1998; Wise et al., 1999). Although VEGF-E does not play 
a role in vascular physiology, it has been used as a VEGFR-2 specific agonist in 
experimental models of angiogenesis in vitro and in vivo. Such studies have indicated that 
VEGF-E expression in the skin of transgenic mice results in an angiogenic phenotype (Kiba 
et al., 2003). Chimeric molecules composed of VEGF-ENZ7 and human PlGF-1 (VEGF-
ENZ7/PlGF) have been proposed to be potent therapeutic angiogenic factors by stimulating 
angiogenesis in response to tissue ischemia and by accelerating skin wound healing (Inoue et 
al., 2007; Zheng et al., 2006; Zheng et al., 2007)  
 
VEGF-like proteins have also been identified from snake (viper) venom. Different snake 
venom VEGFs bind VEGFR-1 and/or VEGFR-2, and vary in their ability to induce 
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angiogenesis and vessel permeability (Gasmi et al., 2000; Gasmi et al., 2002; Junqueira de 
Azevedo et al., 2001; Komori et al., 1999; Takahashi et al., 2004). 
 
 
Table 1.  The molecular features of members of the human VEGF gene family. The asterisks 
indicate heparin binding. References appear in the text. 
 
 VEGF PlGF VEGF-B VEGF-C VEGF-D 
Gene 
(Geneatlas 
database) 
 
15.9 kb 
 
 
13.9 kb 
 
3.71 kb 
 
109.2 kb 
 
38.86 kb 
Chromosome 
location 
6p12 14q24.3 11q13 4q34 Xp22.31 
Protein 
splice 
isoforms 
VEGF121, 
VEGF145*, 
VEGF148*, 
VEGF162*, 
VEGF165*, 
VEGF183*, 
VEGF189*, 
VEGF206 * 
PlGF-1 
(PlGF131), 
PlGF-2* 
(PlGF152), 
PlGF-3 
(PlGF203), 
PlGF-4* 
(PlGF276) 
VEGF-B167*, 
VEGF-B186 
Precursor 
VEGF-C388* 
Precursors 
VEGF-D358*, 
VEGF-D326* 
Sequence 
homology 
 42% 
sequence 
identity to 
VEGF 
45% 
sequence 
identity to 
VEGF 
30% 
sequence 
identity to 
VEGF 
61% 
sequence 
identity to 
VEGF-C; 
31% 
identical to 
VEGF 
Dimerization Homodimers; 
heterodimer 
with VEGF-
B and PlGF 
Homodimers, 
heterodimers 
with VEGF 
Homodimers; 
heterodimers 
with VEGF 
Homodimers; 
heterodimers 
with VEGF-
D 
Homodimers; 
heterodimers 
with VEGF-
C 
 
 
VEGFR-1 
 
VEGFR-1, also known as Flt1 (Fms-like tyrosine kinase 1), is a 180 kDa transmembrane 
glycoprotein, but its mRNA can also be spliced to produce a shorter soluble protein 
consisting only of the first six extracellular Ig homology domains (De Vries et al., 1992; 
Kendall and Thomas, 1993; Shibuya et al., 1990). In the adult, VEGFR-1 is expressed 
mostly on the blood vascular endothelium, vSMCs, monocytes/macrophages, dendritic cells, 
hematopoietic stem cells, trophoblasts, and osteoclasts (reviewed in Shibuya, 2001). The 
VEGF binding domains have been mapped to the 2nd and 3rd extracellular Ig homology 
domains (Keyt et al., 1996). 
 
Several autophosphorylation sites of VEGFR-1 have been identified but the associated 
downstream signaling pathways are poorly known mainly due to its weak tyrosine kinase 
activity (reviewed in Shibuya and Claesson-Welsh, 2006). Interestingly, the pattern of 
VEGFR-1 autophosphorylation induced by VEGF and PlGF were not identical, suggesting 
that the two ligands induce different conformational changes of the intracellular part of the 
receptor, or different association patterns with modifying molecules, such as heparin sulfated 
glycans or neuropilins (Autiero et al., 2003). Targeted inactivation of the VEGFR-1 gene 
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results in embryonic death at E8.5-9.0 due to overgrowth and disorganization of blood 
vessels (Fong et al., 1995; Fong et al., 1999). Deletion of only the intracellular domain of 
VEGFR-1 is compatible with normal vascular development, but impairs pathological 
angiogenesis such as tumor angiogenesis (Hiratsuka et al., 2001; Hiratsuka et al., 1998). 
VEGFR-1 signaling is also involved in monocyte/macrophage migration in response to 
VEGF (Hiratsuka et al., 1998) and in the reconstitution of hematopoiesis by recruiting 
hematopoietic stem cells (Hattori et al., 2002). These results indicate that the ligand-binding 
domain together with the transmembrane domain of VEGFR-1 are adequate to act as a 
negative effector of angiogenesis, most likely by functioning as a “decoy” receptor for 
secreted VEGF (Fong et al., 1999; Hiratsuka et al., 1998). VEGFR-1 activation is also 
reported to result in inhibition of VEGFR-2 (Gille et al., 2000; Zeng et al., 2001). 
Conversely, VEGFR-1 has been suggested to positively adjust VEGFR-2, possibly through 
heterodimerization of the receptors (Autiero et al., 2003; Carmeliet et al., 2001; Huang et al., 
2001). VEGFR-1 stimulation has been shown to be involved in progression of diseases such 
as rheumatoid arthritis and cancer metastasis (reviewed in Shibuya and Claesson-Welsh, 
2006)  
 
VEGFR-2 
 
VEGFR-2, denoted as KDR (kinase insert domain containing receptor) in human and Flk-1 
(Fetal liver kinase 1) in mouse, is a 220 kDa protein with no reported splice variants. 
VEGFR-2 is the main VEGF induced signal transducer in both physiological and 
pathological angiogenesis, mediating proliferation, migration, and survival signals in ECs 
(reviewed in Shibuya and Claesson-Welsh, 2006). VEGFR-2 expression by tip cells confers 
VEGF sensitivity and guided migration of angiogenic sprouts during vascularization 
(Gerhardt et al., 2003). VEGFR-2 is essential for the differentiation of VEGFR-2 positive 
endothelial precursor cells into vascular ECs and VEGFR-2 gene knockout mice die at E8.5-
9.0 due to lack of vasculogenesis (Shalaby et al., 1995). In addition to ECs, VEGFR-2 is 
expressed in hematopoietic stem cells and megakaryocytes (Katoh et al., 1995; Ziegler et al., 
1999). The ligand-binding domains have been mapped to the 2nd and 3rd extracellular Ig 
homology domains (Fuh et al., 1998). 
  
VEGFR-2 stimulation by VEGF leads to autophosphorylation of tyrosine residues (Y) at the 
carboxyterminal region of the receptor. Y1175 appears to be one of the most essential since 
it is a binding site for the SH2 domain of phospholipase-Cγ (PLCγ), which is then tyrosine 
phosphorylated and activates the downstream PKC-c-Raf-MEK-MAP-kinase pathway 
(Takahashi et al., 2001). Knock-in mutant mice with a Tyrosine-to-Phenylalanine 
substitution at position 1173 (equivalent to 1175 in humans) die at E9.0 due to lack of 
vasculogenesis/angiogenesis (Sakurai et al., 2005), suggesting this pathway is important in 
vivo. VEGFR-2 has also been shown to interact with the adapter molecule Shb, TSAd (T-cell 
specific adapter), Akt, VE-cadherin, and integrins such as αvβ3 (Gerber et al., 1998; 
Holmqvist et al., 2004; Shay-Salit et al., 2002; Zeng et al., 2001). VEGFR-2 also mediates 
vascular permeability, probably via Src and Yes (Eliceiri et al., 1999). Recent studies have 
also suggested a role for VEGFR-2 in lymphangiogenesis (Hirakawa et al., 2005; Nagy et al., 
2002).  
 
Lately, a naturally occurring soluble form of VEGFR-2 has been detected in mouse and 
human plasma (Ebos et al., 2004). Similar to soluble VEGFR-1, soluble VEGFR-2 may have 
a regulatory effect in VEGF-mediated angiogenesis.  
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VEGFR-3 
 
VEGFR-3, also denoted as Flt4 (Fms-like tyrosine kinase 4), is a 195 kDa protein, which is, 
unlike VEGFR-1 and VEGFR-2, proteolytically cleaved within the fifth extracellular Ig loop 
into a 120 kDa and a 75 kDa form during synthesis, with the two forms linked by a disulfide 
bond (Lee et al., 1996; Pajusola et al., 1993). The presence of a smaller transcript in humans, 
but not in the mouse, was shown to be due to the insertion of a human retrovirus between the 
last two exons of VEGFR-3 (Hughes, 2001; Pajusola et al., 1993). 
 
VEGFR-3 stimulation leads to autophosphorylation of intracellular tyrosine residues 
(Dixelius et al., 2003). The adaptor molecule Shc has been shown to bind to VEGFR-3 as 
well as Pyk2, which leads to activation of ERK and Jun NH2-terminal kinase (Jnk) and 
tyrosine phosphorylation of the focal adhesion protein paxillin (Wang et al., 1997). VEGFR-
3 also induces PKC dependent activation of the p42/p45 MAPK signaling cascade and PI3K 
dependent Akt phosphorylation to mediate growth and survival of cultured LECs (Makinen 
et al., 2001b). The tyrosine residue Y1068 is necessary for the activation of the VEGFR-3 
kinase domain, whereas Y1063 was shown to be the site for survival signaling via the 
CRK/MKK4/JNK pathway and Y1230/1231 activate the classic PI3K/Akt and ERK 
pathways upon GRB2 reqruitment to the receptor (Salameh et al., 2005). VEGFR-3 has also 
been shown to heterodimerize with VEGFR-2, which leads to differential phosphorylation of 
the receptor and potential activation of different signal transduction pathways in comparison 
to the VEGFR-3 homodimeric configuration (Dixelius et al., 2003). 
 
Loss of the VEGFR-3 gene leads to defective remodeling of the primary vascular plexus and 
cardiovascular failure resulting in embryonic death by E9.5 (Dumont et al., 1998). Therefore, 
the early embryonic function of VEGFR-3 involves blood vascular development. Later, 
VEGFR-3 expression becomes quite specific for LECs (reviewed in Oliver and Detmar, 
2002). VEGFR-3 signaling is required for the formation of the lymphatic vasculature, as 
lymphangiogenesis can be inhibited with a soluble VEGFR-3 (Makinen et al., 2001a). In 
adults, VEGFR-3 is also expressed in fenestrated blood vessels, in monocytes/macrophages, 
in neural progenitor cells, and in osteoblasts (Le Bras et al., 2006; Orlandini et al., 2006; 
Partanen et al., 2000; Schoppmann et al., 2002; Skobe et al., 2001a). VEGFR-3 is also 
upregulated in tumor blood vessels (Laakkonen et al., 2007; Partanen et al., 1999; Valtola et 
al., 1999). Missense mutations in the VEGFR-3 gene that result in inactivation of the 
tyrosine kinase have been linked to primary lymphedema both in humans and in the mouse 
(Karkkainen et al., 2000).  
 
Other VEGF receptors 
 
Neuropilins 
 
Neuropilins (NP-1 and NP-2) are widely expressed cell surface glycoproteins (Kolodkin et 
al., 1997). They function as receptors for the class 3 semaphorins (Sema3s), which are 
secreted molecules involved in axon guidance, as well as coreceptors for several VEGF 
family members (reviewed in Neufeld et al., 2002). NP1 binds VEGF165, VEGF-B167, 
VEGF-B186, PlGF-2, VEGF-C, and VEGF-D (Karpanen et al., 2006; Makinen et al., 1999; 
Migdal et al., 1998; Ober et al., 2004; Soker et al., 1998), whereas NP-2 binds VEGF165, 
VEGF145, PlGF-2, VEGF-C, and VEGF-D (Gluzman-Poltorak et al., 2000; Karpanen et al., 
2006). Due to their short cytoplasmic tails, the NPs probably have no independent signaling 
function, but may act as coreceptors for the VEGFRs. VEGFR-1 interacts with both NP-1 
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and NP-2 (Fuh et al., 2000; Gluzman-Poltorak et al., 2001), while VEGFR-2 interacts only 
with NP-1 (Soker et al., 2002) but not NP-2 (Karpanen et al., 2006). VEGFR-3 has been 
shown to interact with both NP-2 and NP-1 and NP-1 is suggested to modulate the 
angiogenic function of the VEGFR-2 and VEGFR-3 ligands VEGF-C and VEGF-D 
(Karpanen et al., 2006). 
 
Sema3A and VEGF165 compete with each other for NP-1 binding, and Sema3A binding to 
NP-1 in the presence of VEGFR-2 can inhibit VEGF-dependent angiogenesis (Miao et al., 
1999).  Both NPs are expressed in yolk-sac ECs during vasculogenesis (Herzog et al., 2001). 
Later, NP-1 is preferentially expressed in arterial ECs, while NP-2 is expressed in venous 
and lymphatic ECs (Herzog et al., 2001; Yuan et al., 2002). Overexpression of NP-1 in 
transgenic mice resulted in excess capillary formation, blood vessel dilation, and extensive 
hemorrhage (Kitsukawa et al., 1995). Mice defective of NP-1 die at around E13 with both 
severe neuronal defects and disturbed blood vascular development (Kawasaki et al., 1999; 
Kitsukawa et al., 1997). On the other hand, NP-2 deficint mice are viable and only have mild 
neuronal defects and lack small lymphatic capillaries, while blood vessels and larger 
lymphatic vessels are intact (Chen et al., 2000; Giger et al., 2000; Yuan et al., 2002). Double 
knockout of both NP-1 and -2 leads to defects in vasculogenesis and a failure to assemble the 
primary vascular plexus (Takashima et al., 2002).  
 
Heparan sulphate proteoglycans 
 
Heparan sulphate proteoglycans (HSPGs) are a constituent of the ECM and plasma 
membrane. One function of HSPGs is to anchor heparin binding growth factors, thus forming 
protein gradients and thereby altering ligand availability to their receptors. The longer splice 
isoforms of the VEGFs, as well as PlGF-2 and VEGF-B167, bind heparin and heparan sulphate 
proteoglycans (HSPG) on the cell surface and in the ECM via a distinct heparin binding 
domain (Gitay-Goren et al., 1992; Hauser and Weich, 1993; Olofsson et al., 1996b; Persico et 
al., 1999). Heparin binding sites have also been detected in extracellular domains of both 
VEGFR-1 and VEGFR-2, indicating that these receptors may also associate with HSPGs on 
the cell surface (Cohen et al., 1995; Dougher et al., 1997).  
 
Interaction of VEGF with HSPGs anchor VEGF to the cell surface and ECM and creates a 
growth factor gradient which is necessary for correct vessel guidance (Ruhrberg et al., 2002). 
Cell surface HSPGs might induce conformational changes of the receptor or ligand, which 
modifies their interaction. HSPGs might also take part in the formation of signaling 
complexes (Yayon et al., 1991) or in enhancing signaling properties (Jakobsson et al., 2006) 
or protect proteins from proteolytic degradation (Rosengart et al., 1988). 
 
Integrins 
 
Integrins are one of the major families of cell adhesion receptors and are essential for 
embryonic development, proliferation, survival, adhesion, differentiation, and migration of 
cells (Brakebusch and Fassler, 2003). 
Integrins are heterodimeric transmembrane glycoproteins, composed of non-covalently linked 
α and β subunits. 18α and 8β subunits form 24 known αβ heterodimers (Hynes, 2002). Most 
integrin receptors can bind a wide variety of ligands. On the other hand, many extracellular 
matrix and cell suface adhesion proteins can bind to multiple integrin receptors. Many 
different integrins have been shown to have important roles in VEGF-induced angiogenesis 
(Friedlander et al., 1995; Kim et al., 2000; Senger et al., 1997). Integrin αvβ3 directly 
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interacts with VEGFR-2, enhancing kinase activity and mitogenic signaling (Borges et al., 
2000; Soldi et al., 1999). Mice lacking integrin α9β1 die 6-12 days after birth due to 
chylothorax, suggesting a role for α9β1 in lymphatic development or function (Huang et al., 
2000). VEGF-C and VEGF-D induced migration and adhesion of ECs is shown to be 
dependent on integrin α5β1 (Vlahakis et al., 2005). The ECM components collagen and 
fibronectin can, through their binding to β1 integrin, stimulate the tyrosine phosphorylation of 
VEGFR-3 receptor and induce the formation of a β1 integrin-VEGFR-3 receptor complex. 
Furthermore, EC migration requires signals from both the ligand-activated VEGFR-3 and the 
ECM-activated β1 integrin (Wang et al., 2001).  
 
VE-cadherin 
 
Vascular endothelial (VE)-cadherin is the transmembrane component of the adherens 
junctions specifically in ECs. The vascularization process is arrested in VE-cadherin-
deficient embryos at a very primitive stage, indicating that VE-cadherin is required in 
developmental angiogenesis (Gory-Faure et al., 1999). VE-cadherin associates with VEGFR-
2 upon VEGF induction or angiogenic stimulation. This association inhibits VEGFR-2 
phosphorylation by phosphatases at cell-cell contacts (Grazia Lampugnani et al., 2003), 
leading to decreased EC growth and proliferation (Carmeliet et al., 1999; Lambeng et al., 
2005). VEGFR-2-VE-cadherin association is needed for VEGF transduced survival signals 
of ECs via the PI3K/Akt pathway (Carmeliet et al., 1999). VEGF stimulation of VEGFR-2 
triggers association with the VE-cadherin-Src complex which leads to Src phosphorylation 
and then VE-cadherin phosphorylation which again triggers cell-cell disruption (Lambeng et 
al., 2005).  
 
 
5. PLATELET-DERIVED GROWTH FACTORS AND THEIR RECEPTORS 
 
Platelet-derived growth factors (PDGF) constitute a family of disulfide-bonded dimeric 
growth factors: PDGF-AA, -AB, -BB, -CC, and -DD. These factors exert their cellular 
effects through two tyrosine kinase receptors; the structurally related PDGF α- and β-
receptors. The PDGFs contain regularly spaced eight cysteine residues, the cystine knot 
motif, which is involved in inter- and intramolecular bonds. PDGFs are major mitogens for 
several cell types of mesenchymal origin and have important functions during development, 
including regulation of vessel formation and control of the development of organs, e.g. the 
lung and kidney (reviewed in Betsholtz, 2004). 
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Figure 2. Receptor binding of PDGF family members to the PDGFRs.  
 
 
PDGF-A and PDGF-B 
 
PDGF was purified from platelets in the 1970s and was later found to consist of a PDGF-A 
and -B chain, which can act as homodimers or heterodimers. PDGF-AA activates only the 
PDGFR-αα receptor while PDGF-BB and the heterodimer PDGF-AB activate all three 
PDGFR variants, PDGFR-αα, -αβ and -ββ  (reviewed in Betsholtz, 2004). The 
aminoterminal prodomains of these proteins are cleaved intracellularly and are secreted in an 
active form (reviewed in Heldin and Westermark, 1999). Both the A- and B- chains involve 
a basic sequence, which mediates interactions with ECM components and may act as a 
retention signal (Kelly et al., 1993; LaRochelle et al., 1992). PDGF is synthesized by many 
different cell types, such as fibroblasts, vSMCs, ECs, and macrophages (reviewed in Heldin 
and Westermark, 1999). Most cell types expressing PDGF make both A- and B-chains, but 
the expression of the two chains are independently regulated at the transcriptional as well as 
posttranscriptional levels (reviewed in Dirks and Bloemers, 1995). 
 
Deletion of PDGF-A in mice leads to defective development of alveoli of the lung (Lindahl 
et al., 1997b). Loss of PDGF-A also results in a reduced number of intestinal villi. Secretion 
of PDGF-A from intestinal epitelium induces proliferation of PDGFR-α expressing 
mesenchymal cells (Karlsson et al., 2000). PBGF-B is expressed mainly in the developing 
vasculature and has a critical role in the recruitment of PCs to new blood vessels. ECs of 
arteries and angiogenic vessel sprouts secrete PDGF-B, which induces proliferation and 
migration of PDGFR-ββ expressing vascular SMCs and PCs (reviewed in von Tell et al., 
2006). The deletion of PDGF-B in mice leads to embryonic death due to vascular and renal 
dysfunction (Lindahl et al., 1997a). 
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PDGF-C and PDGF-D 
 
PDGF-C and PDGF-D are the most recently discovered growth factors in the PDGF family 
(Bergsten et al., 2001; LaRochelle et al., 2001; Li et al., 2000; Tsai et al., 2000). While the 
classical PDGF-A and PDGF-B primarily encode the growth factor domain, PDGF-C and 
PDGF-D encode a unique two-domain structure with N-terminal complement 
subcomponents C1r/C1s, urchin endothelial growth factor (EGF)-like protein and bone 
morphogenic protein 1 (CUB) domain (Bork and Beckmann, 1993), in addition to the C-
teminal growth factor domain. PDGF-C and PDGF-D proteins form only homodimers as 
proteins (Bergsten et al., 2001; Li et al., 2000).  PDGF-CC activates the PDGFR-αα and -
αβ, while PDGF-DD is regarded as PDGFR-ββ specific (Bergsten et al., 2001; Gilbertson et 
al., 2001; LaRochelle et al., 2001; Li et al., 2000). Knock-out studies of PDGF-C have 
shown that PDGF-C has a specific role in palatogenesis and in morphogenesis of the skin 
(Ding et al., 2004). A PDGF-D knockout has not been reported. PDGF-C and PDGF-D have 
been shown to have broad expression patterns and to have potentially important roles during 
normal embryogenesis and maintenance of adult tissues, as well as in various pathological 
conditions such as renal disease, fibrosis, and cancer (reviewed in Reigstad et al., 2005). 
 
PDGFR-α and PDGFR-β 
 
PDGFR-α and -β have a molecular size of 170 kDa and 180 kDa, respectively, and consist 
of five extracellular immunoglobulin-like domains and an intracellular tyrosine kinase 
domain (Claesson-Welsh, 1989; Matsui et al., 1989). The receptors dimerize upon growth 
factor binding and can form both homo- and heterodimeric receptor complexes (Kanakaraj et 
al., 1991). PDGFRs are present on connective tissue cells such as fibroblasts and vSMCs, but 
they have also been detected on other cell types (Heldin and Westermark, 1999). PDGF 
receptor signaling is associated with various pathological conditions, including different 
fibrotic diseases and various vasculoproliferative diseases (reviewed in Bonner, 2004; 
Raines, 2004). 
 
Deletion of either PDGFR leads to embryonic lethality. PDGFR-α appears to be needed for 
promoting the proliferation of precursor populations in cell types including lung alveolar 
SMCs, oligodendrocytes, intestinal villi, and dermal papillae (Lindahl, 1998). PDGFR-β null 
animals have severe defects in the vSMC and PC populations, similar to PDGF-B deficient 
mice. The most severely affected of this cell type are vSMCs and PCs in different organs 
such as the brain, heart, kidney, skin, and eye (Lindahl et al., 1997a; Lindahl, 1998; Soriano, 
1994).  
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AIMS OF THE STUDY 
 
This study was undertaken to address the role of VEGFR specific signaling in angiogenesis 
and lymphangiogenesis. The specific aims for the study were: 
 
 
I  To study VEGFR-2 induced vessel formation and establishment by PDGF-D 
 
II To clarify the role of VEGFR-2 in lymphangiogenesis and to study 
angiogenesis mediated by specific VEGFR-1 or VEGFR-2 stimulation 
 
III  To study inhibition of VEGFR-3 postnatally under normal conditions and 
VEGFR-3 ligand dependency on postnatal lymphatic vessel maturation 
 
IV To investigate the effects of a small-molecular tyrosine kinase inhibitor, 
AZD2171, on lymphangiogenesis 
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MATERIALS AND METHODS 
 
The materials and methods are described in detail in the original publications, which are here 
referred to using Roman numerals. 
 
Production and use of adeno-associated viruses  (I) 
 
Full-length VEGF-E, full-length and short-form of PDGF-D, full-length PDGF-B and human 
serum albumin cDNAs were cloned into the AAV vector. Recombinant AAVs were 
produced as described previously and tested in vitro using metabolically labeled cell lysates 
with analysis by immunoprecipitation and SDS-PAGE. 
 
Fifty microliters purified AAV (5 x 1011 genomic particles/ml) was injected into the subcutis 
of the ear or the gastrocnemius muscle of FVB/n or NMRI nu/nu mice. Four weeks later, the 
mice were sacrificed and the tissues were analyzed. 
 
The blood vessels in whole mount preparations of the AAV-transduced mouse skin were 
visualized using antibodies against BECs (PECAM-1) and vSMCs (SMA). The results of the 
whole mount analysis were confirmed by staining frozen or paraffin embedded tissue 
sections with antibodies against BECs (PECAM-1), vSMCs (SMA), and macrophages 
(F4/80). Blood vessel permeability was studied by comparing vascular leakage in ear skin 
after intravenous injection of a fluorescent dye.  
 
Generation and analysis of K14-PDGF-D transgenic mice (I) 
 
Human PDGF-D cDNA was cloned into the K14 promoter expression vector. A 5 ng/ml 
solution of the DNA was injected into fertilized eggs of the FVB/n-strain of mice, and the 
resultant transgenic mice were maintained in this strain. For the analysis of transgene 
expression, we examined PDGF-D mRNA levels by northern blot and protein expression by 
immunohistochemistry using anti-PDGF-D antibodies.  
 
The skin was analyzed by immunohistochemistry using antibodies against BECs (PECAM-
1), smooth muscle cells (SMA), lymphatic vessels (VEGFR-3 and LYVE-1), hematopoietic 
cells (CD45), T-lymphocytes (CD3), B-lymphocytes (B-220), granulocytes (Ly-6G), and 
macrophages (F4/80). Interstitial fluid pressure was measured from the skin by using the 
modified Wick technique. The function of skin lymphatic vessels was analyzed by 
fluorescent microlymphangiography. 
 
To investigate the possible role for PDGF-D in wound healing, two circular wounds were 
made on both sides of the back of the mice using a 5 mm punch-biopsy tool. The wounds 
were allowed to heal for up to 10 days, after which the mice were sacrifized and the wounds 
were collected. Sections of the wounds were stained with haematoxylin and eosin. To 
evaluate the amount of connective tissue in skin and wound, the samples were stained with 
Van Gieson and Masson trichrome stains.   
 
Analysis of blood and lymphatic vessels (II- IV) 
 
The blood and lymphatic vessels in whole mount preparations of mouse tissue were 
visualized using antibodies against BECs (PECAM-1 and VEGFR-2), SMCs (SMA), or 
LECs (LYVE-1 and VEGFR-3).  
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Staged embryos of the different transgenic mice mated in the VEGFR-2+/LacZ or VEGFR-
3+/LacZ background were stained for ß-galactosidase activity at 37°C. 
 
The results from the whole mount analysis were confirmed by staining frozen or paraffin 
embedded tissue sections with antibodies against BECs, smooth muscle cells, inflammatory 
cells (CD11b), LECs, or the proliferation marker BrdU. 
 
The effects of VEGFs on blood vessel permeability were studied by comparing vascular 
leakage in transgenic mouse ear skin after an intravenous injection of Evans blue dye or 
FITC-dextran. Microcirculation was measured from the base of the ear by a laser-doppler 
flowmeter. The function of skin lymphatic vessels was analyzed by fluorescent 
microlymphangiography.  
 
Cell stimulation and western blot analysis (II) 
 
Porcine aortic endothelial (PAE) cells stably overexpressing VEGFR-2 or VEGFR-3 were 
starved overnight in serum-free medium and incubated for 20 min with soluble VEGFR-2-Ig 
or VEGFR-3-Ig fusion proteins or rat monoclonal antibodies against human VEGFR-2 at a 
concentration of 1 µg/ml. The cells were then stimulated for 10 min with recombinant 
VEGF-E or VEGF-C, lysed, and immunoprecipitated with antibodies against VEGFR-3 or 
VEGFR-2. Phosphotyrosine-specific antibodies and antibodies against VEGFR-2 or 
VEGFR-3 were used for detection of proteins in western blot. 
 
Generation and use of recombinant adenoviruses (II, III, IV) 
 
Full length VEGF-E cDNA was cloned into the pAdapt vector. The adenoviruses encoding 
VEGF-E, VEGF164, VEGF165, VEGF-C, VEGFR-2-Ig, VEGFR-3-Ig, and nuclear-targeted 
LacZ were produced as previously described. Analysis of protein expression was performed 
in vitro using metabolically labeled cell lysates and immunoprecipitation with SDS-PAGE. 
 
Lymphatic sprouting inhibition studies with adenoviruses (II) 
 
2.5 x 108 pfu of recombinant adenoviruses encoding VEGF-C, VEGF-E, VEGF164, 
VEGF165, or LacZ were injected intradermally into female NMRI nu/nu mice. The skin was 
analyzed 4 days later. For inhibition experiments, 1 x 109 pfu of VEGFR-3-Ig or LacZ 
adenoviruses were injected intravenously 3 days prior to the ligand encoding adenoviruses.  
 
For sprouting inhibition experiments, the mice were injected intraperitoneally with 600 µg of 
mF4-31C1, a rat monoclonal antibody against mouse VEGFR-3, DC101, a rat monoclonal 
antibody against mouse VEGFR-2, or rat IgG every second day in a volume of 200 µl.  One 
day later, 2.5 x 108 pfu of recombinant adenoviruses encoding VEGF-C, VEGF-C156S, 
VEGF-E, or LacZ were injected intradermally into the ears of the same mice. The lymphatic 
and blood vessels in the skin were analyzed by whole mount stainings and 
immunohistochemistry as described above. 
 
Matings and analysis of transgenic mice (II) 
 
The single transgenic mice used in this study were all previously published. The aim was to 
study the angiogenic and lymphangiogenic effects of overexpression of different VEGFR-
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specific ligands alone and in combinations. The growth factors were expressed under the 
K14-promoter, which has been shown to target expression of transgenes appropriately to 
cells of squamous epithelia. The heterozygous VEGFR-2+/LacZ and VEGFR-3+/LacZ mice 
were used for visualization of VEGFR-2 and VEGFR-3 expression in blood and lymphatic 
vessels.  All the mouse strains used are listed in Table 2. The analysis of blood and 
lymphatic vessels in the mice were analyzed as described above. 
 
Table 2. Transgenic mice lines used in study II. 
 
Mouse line Reference 
K14-VEGF-E (Kiba et al., 2003) 
K14-PlGF (Odorisio et al., 2002)  
K14-VEGF-C156S (Veikkola et al., 2001) 
K14-VEGFR-3-Ig (Makinen et al., 2001a) 
K14-VEGF-D (Veikkola et al., 2001) 
VEGFR-2+/LacZ (Shalaby et al., 1995) 
VEGFR-3+/LacZ  (Dumont et al., 1998) 
K14-VEGF165 (Zheng et al., 2006) 
K14-VEGF-C (Jeltsch et al., 1997) 
K14-VEGF-E × K14-PlGF II 
K14-VEGF-E × K14-VEGF-C156S II 
K14-VEGF-E × K14-VEGFR-3-Ig II 
K14-VEGF-E × VEGFR-2+/LacZ II 
K14-VEGF-E × VEGFR-3+/LacZ II 
  
Treatment of mice with adenovirus-encoded ligand traps, blocking antibodies, or 
recombinant proteins (III) 
 
The transgenic mice used in the study were VEGFR-3+/LacZ, K14-VEGF-C, K14-VEGF-
C156S, and K14-VEGF-D mice and they have all been described previously. NMRI nu/nu 
and nu/+ mice were from obtained from Harlan. 
 
One-, four-, or seven-day-old mouse pups were injected intraperitoneally with 5 × 108 pfu 
and mice 14 days or older with 1 × 109 pfu of AdVEGFR-3-Ig, AdVEGFR-2-Ig, AdLacZ, or 
PBS. Mice were injected intraperitoneally once a day or every second day with 30 mg/kg or 
60 mg/kg of mF4-31C1, a rat monoclonal antibody against mouse VEGFR-3 that blocks 
ligand binding; 25 mg/kg of recombinant VEGFR-3-Ig fusion protein; 20 mg/kg AFL4, a rat 
monoclonal antibody against mouse VEGFR-3 that blocks ligand binding; or control 
antibodies in a volume of 20 to 100 µl. Mice were sacrificed at different time points and 
analysis of lymphatic and blood vessels was done using whole mount stainings, 
immunohistochemistry and lymphangiography as described above. 
 
To test VEGFR-3-Ig binding properties, sera obtained from AdVEGFR-3-Ig-transduced 
mice were used to precipitate metabolically labeled VEGF-C from the conditioned medium 
of VEGF-C-transfected 293T cells. 
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Systemic half-life measurement of mF4-31C1 and VEGFR-3-Ig (III) 
 
Female nu/nu mice were injected intraperitoneally with 20 mg/kg of mF4-31C1 or 
intravenously with 10 µg of recombinant VEGFR-3-Ig protein and blood samples were 
collected at the indicated time points. Plasma concentration of mF4-31C1 or VEGFR-3-Ig 
was determined using an enzyme-linked immunosorbent assay. The change in optical density 
was measured using a microplate reader. Pharmacokinetic parameters of mF4-31C1 were 
calculated by noncompartmental analysis using the WinNonlin program. 
 
Cell stimulation, co-precipitation, and proliferation assays (IV) 
 
For the receptor phosphorylation studies, HDMVECs were plated on 15-cm dishes pretreated 
with human fibronectin and grown to confluency. The cells were serum starved overnight at 
37°C. AZD2171 or DMSO as a control were added to the cells and incubation carried out for 
15 min at 37°C.  VEGFC-156S, VEGF-E or BSA (control protein) was added to the cells at a 
final concentration of 500 ng/ml and the cells incubated at 37°C for 10 min. Following 
stimulation the cells were lysed and immunoprecipitated with anti-VEGFR-2 or anti-
VEGFR-3 antibodies and analyzed by western blot. The phosphorylation of the receptors 
was detected using the anti-phosphotyrosine antibody.  
 
For detection of downstream signaling mediators of VEGFR-2 and VEGFR-3 activity, 
HDMVECs were grown to confluency on fibronectin coated 10 cm dishes. The cells were 
serum-starved overnight and DMSO or AZD2171 was added and cells incubated as above 
before stimulation with VEGF-C156S or VEGF-E. Detection was carried out from cell 
lysates by western blot using anti-phospho-p44/42 MAPK, anti-phospho-Akt, and anti-
phospho-CREB and anti-α-Actin antibodies.  
 
For EC proliferation assay, the HDMVECs were seeded on fibronectin coated glass 
coverslips and grown to near-confluency. The medium was replaced with serum-free 
medium and the cells treated with the AZD2171 compound or DMSO for 15 min followed 
by the addition of VEGF-E or VEGF-C156S at 500 ng/ml. The incubation was continued for 
20 hours. The last hour of incubation was carried out with 50 µM BrdU supplemented to the 
media. The cells were fixed and stained. Replicating nuclei were detected using the anti-
BrdU antibody and LECs distinguished from BECs using the LYVE-1 antibody.  
 
Inhibition of adenovirally or tumor cell-induced lymphangiogenesis and angiogenesis 
by the tyrosine kinase inhibitor AZD2171 (IV) 
 
5 x 108 pfu of recombinant adenoviruses encoding VEGF-C, VEGF-C156S, VEGF-E,  
nuclear targeted LacZ, or GFP-tagged LNM35 (human non-small cell lung adenocarcinoma) 
cells suspended in Matrigel at a concentration of 2×105 cells/10µl were injected 
intradermally into 6-8 weeks old male NMRI nu/nu mice. The tyrosine inhibitor AZD2171 
or 1% polysorbate (control vehicle) were given orally to the same mice once a day. The skin 
was analyzed 6 days later for the adenovirus treated ears and 7 days later for the tumor 
implanted ears. The ears were prepared for whole mount staining to visualize lymphatic and 
blood vessels as described above.  
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RESULTS AND DISCUSSION 
 
The main results of the studies are summarized here. The results are presented and discussed 
in more detail in the accompanying original publications, which are here referred to using 
Roman numerals.  
 
 
PDGF-D in blood vessel maturation and macrophage accumulation (I) 
 
Despite its promise for treating ischemic diseases, VEGF can induce the growth of aberrant 
blood vessels and this could limit its therapeutic utility. In addition, some animal 
experiments have indicated that instead of stimulating angiogenesis, constant delivery of 
high levels of VEGF can result in the development of vascular malformations or 
hemangiomas (Dor et al., 2002; Lee et al., 2000; Pettersson et al., 2000). 
 
Genes with sequence homology to VEGF have been discovered in Orf viruses and in 
pseudocowpox viruses. These virus-encoded VEGFs, commonly named VEGF-E, 
specifically bind VEGFR-2 but not VEGFR-1, and although VEGF-E does not play a role in 
vascular physiology, it can be used in experimental models to study VEGFR-2 specific 
responses in vitro and in vivo. VEGF-E has a strong angiogenic effect in transgenic mice 
(Kiba et al., 2003). We wanted to determine if we could obtain the same effect in a more 
therapeutially applicable model using recombinant AAVs. 
 
AAVs encoding VEGF-E, PDGF-B, or PDGF-D were generated and shown to produce 
active transgene-encoded proteins in infected cell cultures. AAV-VEGF-E indeed induced a 
strong angiogenic effect when injected into mouse ear or into gastrocnemius muscle. On the 
other hand, neither PDGF-B nor PDGF-D had any angiogenic effect. Functional analysis of 
blood vessel permeability showed that VEGF-E induced blood vessels were leaky and the 
smooth muscle cell layer that surrounds the larger arteries and veins was irregular, 
presumably the cause for the vascular leakage. Interestingly, when we used combinations of 
AAV-VEGF-E and either AAV-PDGF-B or AAV-PDGF-D, the vascular leakage was 
significantly reduced and the smooth muscle cell layer appeared normal. This indicates that 
PDGF-D and PDGF-B are capable of stabilizing newly formed vessels through their effects 
on the SMCs.  
 
The PDGF-D induced stabilization of VEGF-E induced new blood vessels was also 
confirmed in transgenic mice. When K14-VEGF-E mice (Kiba et al., 2003) were mated with 
the K14-PDGF-D mice the leakiness was reduced similar to the results obtained with the 
AAVs (M. Wirzenius and M. Uutela, unpublished data) 
 
To study the biologic functions mediated by PDGF-D, we also created transgenic mice 
where full-length PDGF-D was expressed under the control of the K14 promoter in the basal 
epidermal keratinocytes. Our results show that overexpression of PDGF-D in skin increased 
macrophage recruitment into the unperturbed skin and that this effect was enhanced during 
the wound healing process. Previous studies have shown that PDGF-B induces macrophage 
migration through PDGFR-β (Siegbahn et al., 1990) although PDGF-D appeared to be more 
potent in stimulation of these cells.  
 
The K14-PDGF-D mice also displayed increased interstitial fluid pressure (IFP), consistent 
with the fact that PDGFR-β is essential for the maintenance of steady state IFP (Pietras et al., 
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2001). Tumors often have increased IFP, making it more difficult to deliver cancer 
chemotherapeutics. Using PDGFR-β inhibitors to lower the tumor IFP, and which would 
simultaneously decrease the SMC coverage of the tumor blood vessels, could have clinical 
benefits for cancer patients.  
  
Since its discovery six years ago, PDGF-D has been linked to important functions both in 
embryogenesis and in adult tissues (reviewed in Reigstad et al., 2005). Most information on 
PDGF-D biology has been obtained from studies using the kidney as a model organ. PDGF-
D is a likely candidate for controling the progression of metastatic renal cell carcinoma since 
its overexpression enhanced tumor progression and metastasis in mice. As a summary, our 
results indicate that PDGF-D has significant ability to regulate macrophage recruitment and 
participates in the control of tissue IFP. Both PDGF-D and PDGF-B improve the SMC 
coating of blood vessels during neoangiogenesis and decrease their permeability, thus being 
attractive candidates for use in local angiogenic gene therapy.  
 
 
VEGFR-2 signaling in lymphangiogenesis (II) 
 
Even though VEGF is one of the most important regulators of both physiological and 
pathological angiogenesis, recent studies have suggested that VEGF also can induce 
lymphangiogenesis (Hirakawa et al., 2005; Nagy et al., 2002). However, the signaling 
mechanisms mediating this response have been unclear.  
 
We analyzed the roles of different VEGF receptors in lymphangiogenesis by using 
adenoviral and transgenic overexpression of VEGF family members in mouse skin, 
combined with the use of antibodies blocking specific VEGF receptors. In particular, 
overexpression of PlGF and VEGF-E allowed specific stimulation of VEGFR-1 and 
VEGFR-2, respectively. Our data showed that stimulation of VEGFR-2 induces hyperplasia 
of the lymphatic vessels but very few vessel sprouts in postnatal mice. On the other hand, we 
could not detect any lymphatic phenotype when only VEGFR-1 was activated by 
overexpression of PlGF. This indicates that the lymphatic vascular effects induced by 
overexpression of VEGF, as seen by us and others, are indeed mediated primarily via 
VEGFR-2. 
 
VEGFR-2 expression has been shown to be high in the endothelial tip cells of blood vessels, 
which through their filopodia sense the VEGF gradient to guide blood vascular sprouting 
(Gerhardt et al., 2003). We showed that the sprouting mechanism of lymphatic vessels is 
not dependent on VEGFR-2 in adults. Overexpression of VEGF-E did not lead to sprouting 
of lymphatic vessels but rather to circumferential growth. In addition, the sprouting of 
lymphatic vessels induced by adenoviral VEGF-C could not be blocked with neutralizing 
antibodies against VEGFR-2. These results suggest that the sprouting mechanisms of 
lymphatic vessels in adults do not rely on VEGFR-2, and thus differ from those of blood 
vessels.  
 
Surprisingly, VEGF-E did not induce changes in the lymphatic vasculature during embryonic 
development. Although VEGF-E stimulated lymphatic vessel enlargement in postnatal mice, 
we did not detect any increase in the number of lymphatic vessels in the K14-VEGF-E mice 
at any age of analysis. This indicates that signaling through VEGFR-2 does not induce 
lymphangiogenesis during embryonic development, but its effects become apparent during 
the postnatal period upon maturation of blood and lymphatic vessels. One possibility was 
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that at least some of the hyperplasia was a secondary effect resulting from the vascular 
leakage promoted by VEGF-E overexpression. The lymphatic hyperplasia started after the 
effects of VEGF-E in the blood vessels became apparent and both the vascular leakage and 
the lymphatic hyperplasia could be reduced by PlGF overexpression that apparently reduced 
blood flow via increased coating of small vessels by SMCs. However, from additional 
experiments we learned that vascular leakage alone was not sufficient for the hyperplasia, as 
the lymphatic vessels of the K14-PlGF mice appeared to be normal although their blood 
vessels were even leakier than those in the K14-VEGF-E mice. We cannot currently explain 
the late onset of the effects of the K14-VEGF-E transgene despite its high-level expression 
starting during the embryonic period. It may be speculated that in vivo particular pericellular 
matrix proteins and integrins are required for specific VEGFR-2 activation by VEGF-E and 
that they are not present until later in development.  
 
We also found that VEGF-E overexpression was not able to rescue the lymphatic regression 
induced by blocking VEGF-C and VEGF-D. This result indicates that VEGFR-2 cannot 
substitute for VEGFR-3 signals during the onset of lymphangiogenesis. VEGFR-3 was 
expressed strongly in lymphatic capillaries, and it was internalized into the lymphatic ECs 
after adenoviral VEGF-C stimulation, but not after VEGF-E stimulation, suggesting that 
VEGF-E does not lead to signaling via this receptor. VEGFR-2 was expressed in both 
lymphatic capillaries and collecting lymphatic vessels in wild-type mice. However, VEGFR-
2 was internalized in both types of vessels upon AdVEGF-E or AdVEGF-C transduction, 
indicating that the receptor was functional. 
 
It is still not clear to what extent the VEGFR-2 stimulated lymphatic effect is primary or 
secondary. The K14 expression cassette has been shown to target expression of transgenes 
appropriately to epithelial cells, such as epithelial basal cells of the skin, the cornea, eyelids, 
ears, tongue, esophagus and forestomach (Nelson and Sun, 1983). We analyzed the blood 
and lymphatic vasculature also in these organs and found increased angiogenesis, but 
interestingly no hyperplasia of lymphatic vessels (unpublished data by M. Wirzenius). These 
results indicate that at least to some extent the lymphatic effects through VEGFR-2 are of 
secondary character. We have also observed that K14-VEGF-E+PlGF double transgenic 
mice developed highly vascularized hemangiomas around their mouth. These lesions also 
contained more and larger lymphatic vessels than the wild type skin taken from the mouth 
area, presumably secondary to the edema in the snout skin. The K14-VEGF-E+PlGF double 
transgenic mice were considerably smaller in size than the K14-VEGF-E and K14-PlGF or 
wild type littermate mice. We also wanted to investigate if the small size of the double K14-
VEGF-E+PlGF mice affected the relative weight of the hearts of these mice. The hearts of 
the double K14-VEGF-E+PlGF mice were significantly bigger in relation to the size of the 
mice compared to their wild type littermates. The heart sizes of both K14-VEGF-E and K14-
PlGF mice were normal. We did not observe any hypertrophy of the hearts of the K14-
VEGF-E+PlGF mice and no differences of the blood or lymphatic vasculature between the 
hearts of the K14-VEGF-E+PlGF mice and their wild type littermates.  
 
In conclusion, we showed here that overexpression of a VEGFR-2 specific ligand induces 
circumferential hyperplasia of the lymphatic vessels in adult, but not in embryonic skin. 
However, VEGFR-2 activation is not sufficient for the generation of new lymphatic vessels 
and it was not able to rescue the lymphatic regression induced by blocking the VEGFR-3 
ligands VEGF-C and VEGF-D. These results specify the contribution of the different VEGF 
receptor pathways to lymphangiogenesis and reveal previously unknown postnatal changes 
that occur in the sensitivity of both blood and lymphatic vessels towards VEGF family 
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ligands. Taken together, the VEGF/VEGFR system needs to be strictly controlled during 
development but also in adult life. 
 
Lymphatic vessels are independent of VEGFR-3 signaling in adults but not during 
postnatal lymphatic vessel maturation (III) 
 
The spread of cancer cells through lymphatic vessels into regional lymph nodes is commonly 
the first step in the dissemination of human cancer. A correlation between VEGF-C 
expression by the primary tumor and metastasis to the sentinel lymph nodes has been 
reported for several types of human cancers (reviewed in Stacker et al., 2002b). 
Overexpression of VEGF-C and VEGF-D in experimental tumors has been shown to induce 
tumor lymphangiogenesis and to promote tumor metastasis (reviwed in Saharinen et al., 
2004). Furthermore, VEGF-C/D-induced tumor lymphangiogenesis and lymphatic metastasis 
can be inhibited by blocking the interaction of VEGFR-3 with its ligands (He et al., 2002; 
Karpanen et al., 2001). 
 
In this study we treated mice of different ages with adenoviral overexpression of the soluble 
VEGFR-3-Ig fusion protein, blocking antibodies against VEGFR-3, or recombinant VEGFR-
3-Ig fusion proteins. We showed that inhibition of VEGFR-3 signaling results in regression 
of lymphatic capillaries and medium-sized lymphatic vessels during the first 2 weeks after 
birth. However, the lymphatic vasculature starts to regenerate by the age of 4 weeks.  
 
Mice heterozygous for VEGF-C deficiency (Karkkainen et al., 2004), the Chy mice, which 
have an inactivating mutation in the VEGFR-3 gene (Karkkainen et al., 2001), as well as 
mice expressing VEGFR-3-Ig under a keratin promoter in the skin (Makinen et al., 2001a) 
are born essentially without lymphatic capillaries, whereas their large collecting lymphatic 
vessels appear normal. However, in these mice, lymphatic vascular regeneration occurs in 
the internal organs but not in the skin starting at 2 weeks of age. Postnatal regeneration of 
lymphatic capillaries in most tissues, including the skin, has also been observed in mice 
deficient of NP-2 (Yuan et al., 2002), which acts as a co-receptor for VEGF-C. It is not yet 
known where lymphatic regeneration starts from in these various mice. The large lymphatic 
vessels in the NP-2-deficient mice and the lymphatic remnants in the AdVEGFR-3-Ig-treated 
mice could serve as origins of lymphatic sprouting. In contrast, the lymphatic vessels are 
almost completely absent from the skin of the heterozygous VEGF-C gene targeted mice, 
Chy mice, and K14-VEGFR-3-Ig mice. 
Although the VEGF-C/VEGFR-3 pathway is not needed in adult mice for the growth of 
lymphatic vessels, it is apparently functional, because lymphangiogenesis can be stimulated 
by VEGF-C, when delivered for example via an adenovirus (Enholm et al., 2001) (Saaristo 
et al., 2002a). Possible postnatal factors responsible for the VEGF-C/VEGF-D/VEGFR-3-
independent pathway could be VEGF (Hirakawa et al., 2005; Nagy et al., 2002), HGF  
(Kajiya et al., 2005), and the angiopoietins (Tammela et al., 2005b), which have all been 
shown to stimulate lymphangiogenesis. Another possibility is that the extracellular matrix 
provides important stabilizing growth-promoting signals for lymphatic vessels in adults, 
possibly mediated by integrins. It has previously been shown that integrin β1 can directly 
interact with VEGFR-3 and modulate its phosphorylation, thus affecting lymphatic EC 
migration (Wang et al., 2001). Integrin α9β1-deficient mice die 6 to 12 days after birth 
because of chylothorax caused by a failure of lymphatic vessels, which indicates a crucial 
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function for integrin α9β1 in lymphatic development (Huang et al., 2000). Indeed, integrin 
α9β1 was shown to directly bind VEGF-C and VEGF-D and to promote EC adhesion and 
migration (Vlahakis et al., 2005). 
We also used adenoviral VEGFR-2-Ig similar to VEGFR-3-Ig in an attempt to postnatally 
inhibit the growth of lymphatic or blood vessels. We did not notice any effects on the 
lymphatic vessels, which could suggest that the VEGFR-2 signaling system in lymphatic 
vessels is not as active and important in postnatal life, even though signaling through 
VEGFR-2 has been shown to be involved in postnatal lymphatic vessel growth (Hirakawa et 
al., 2005; Nagy et al., 2002). Interestingly, we did not notice any effect on the blood vessels 
either, which is surprising considering that VEGF gene deletion or daily administration of 
VEGFR-1-Ig in postnatal mice has been shown to result in EC apoptosis, leading to severely 
reduced numbers of blood vessels and increased postnatal lethality (Gerber et al., 1999).  
In summary, our study suggests that the blocking of VEGF-C and VEGF-D should be a safe 
method to inhibit tumor metastasis, because normal lymphatic vessels are not affected by 
such treatment in adults. 
The small-molecular tyrosine kinase inhibitor AZD2171 potently inhibits 
lymphangiogenesis (IV) 
Anti-angiogenic therapy by antibodies against the VEGFR-2 signaling system has been 
shown to be beneficial for treatment of some solid tumors. In addition, the formation of 
lymph node metastasis can be inhibited with a soluble form of VEGFR-3 or a monoclonal 
antibody targeting the receptor (He et al., 2002; Roberts et al., 2006). VEGFR-3 may also 
have a role in pathological angiogenesis, such as tumor blood vessel formation, and the use 
of a VEGFR-3 specific antibody has been shown to reduce primary tumor growth 
(Laakkonen et al., 2007). Inhibition of VEGFR-3 activity will therefore likely be 
therapeutically beneficial. The disadvantage of using therapies against specific molecules is 
the fact that tumors sometimes become resistant to treatment. In addition, the processes 
mediating cancer growth and progression are complex and involve a number of molecules. 
Inhibitors targeting multiple molecules or pathways could make it more difficult for the 
tumors to become resistant and therefore these drugs could be more efficacious. 
 
AZD2171 is an indole-ether quinazoline, which competes for ATP binding on the catalytic 
domain of VEGFR-2, and has been shown to be an effective inhibitor of VEGF-induced 
signaling and angiogenesis, with additional activity against VEGFR-1 and VEGFR-3 
(Wedge et al., 2005). In this study we used the specific VEGFR-2 ligand VEGF-E and the 
specific VEGFR-3 ligand VEGF-C156S to compare the ability to AZD2171 to block 
signaling from the main angiogenic and lymphangiogenic receptors. Activation of VEGFR-2 
in primary human ECs by VEGF-E results in autophosphorylation of the receptor as well as 
increased phosphorylation of downstream signaling molecules and increased cellular 
functions such as proliferation, survival, migration, and tube formation.  Specific activation 
of VEGFR-3 by VEGF-C156S results in a similar cascade of signaling events all of which 
could be blocked with the same dose of AZD2171 required for inhibition of VEGFR-2 
activity. These results demonstrate that AZD2171 has comparable inhibitory activity against 
VEGFR-2 and VEGFR-3-induced cell phenotypes, and cells dependent on signaling from 
either receptor would be inhibited by similar doses of AZD2171. 
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In vivo, stimulation of VEGFR-2 by VEGF-E results in increased angiogenesis as well as 
lymphatic vessel enlargement. Similar to the effects of VEGF-C, VEGF-C156S induces 
lymphangiogenesis in vivo. Once daily oral treatment with AZD2171 was sufficient to block 
VEGF-E induced neovascularization as well as VEGF-C and VEGF-C156S induced 
lymphagiogenesis in vivo. These results suggest that physiological and pathological 
processes dependent on VEGFR-2 or VEGFR-3 driven angiogenesis or lymphangiogenesis 
would be equally affected by AZD2171 treatment. To investigate tumor cell induced 
lymphangiogenesis, we injected the human lung carcinoma cell line LNM35 subcutneously 
into the mouse ear. We observed the formation of lymphatic vessels around the VEGF-C 
expressing tumor cells, but lymphatic vessel formation was inhibited with AZD2171 
treatment.  
 
Tumor progression involves a number of processes each of which may be mediated by a 
number of different molecules. Tumor-induced neovascularization is a complex event and 
may require inhibition of more than one molecule. Small molecular tyrosine kinase inhibitors 
such as AZD2171 are therefore attractive for their ability to block activity of multiple 
targets. These results indicate that AZD2171 may prove beneficial in the clinics, not only by 
inhibiting new tumor blood vessel growth, but also by preventing the spread of cancer cells 
through simultaneous inhibition of tumor-associated lymphangiogenesis. 
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CONCLUDING REMARKS  
 
Both blood and lymphatic vessels have been identified to play an important role in several 
physiological and pathological conditions and the capability to control their growth is of 
great importance. While anti-angiogenic therapy could be useful for patients suffering from 
increased angiogenesis, as in cancer or some forms of diabetes, stimulation of angiogenesis 
could be useful for patients suffering from heart ischemia or diabetes-related ischemia in the 
extremities. Similarly, while anti-lymphangiogenic therapy may be beneficial in preventing 
further cancer cell spread via lymphatic vessels, stimulation of lymphangiogenesis might 
help patients with hereditary or surgery-related lymphedema.  
 
In the present study we have further characterized the VEGFR specific effects on 
angiogenesis as well as lymphangiogenesis by overexpressing different VEGFR specific 
ligands. We showed that while stimulation of blood vessels by the VEGFR-2 specific ligand 
VEGF-E lead to new and extremely permeable blood vessels, a combination of VEGF-E and 
either PDGF-B or PDGF-D leads to mature functional vessels. In addition, we showed that 
overexpression of VEGF-E induces circumferential hyperplasia of lymphatic vessels in the 
adult, while the VEGFR-1 specific ligand PlGF did not have any effect on lymphatic vessels. 
However, VEGFR-2 activation alone was not sufficient for the generation of new lymphatic 
vessels and it was not able to rescue the lymphatic regression induced by blocking the 
VEGFR-3 ligands VEGF-C and VEGF-D. Our results suggest that the sprouting mechanisms 
of lymphatic vessels in adults do not rely on VEGFR-2, and thus differ from those of blood 
vessels. These results specify the contribution of the different VEGF receptor pathways to 
lymphangiogenesis and reveal previously unknown postnatal changes that occur in the 
sensitivity of both blood and lymphatic vessels towards the VEGF family of ligands. 
 
A challenge for future research is to find out why some members of the VEGF growth factor 
family are activated early during development while others are activated only later in 
postnatal life. Why does overexpression of VEGF-D not induce lymphangiogenesis during 
embryogenic development while VEGF-C does, even though their functions are both 
primarily mediated by VEGFR-3? Why does VEGFR-2 stimulation by VEGF-E not induce 
angiogenesis prenatally while VEGFR-1 stimulation by PlGF does? Can the growth factors 
and their receptors utilize alternative signaling systems and if so, what are these other 
systems? This could shed light on why for example some tumors become resistant to anti-
angiogenic therapy. How these different growth factors and receptors work during 
pathological conditions is only starting to be elucidated.  
 
The members of the VEGF family and their receptors appear to provide promising and 
versatile targets for the therapeutic manipulation of angiogenesis and lymphangiogenesis and 
the pathological situations associated with them. Therefore it’s extremely important to 
acquire a deeper understanding of the basic mechanisms connected with the different VEGF 
growth factors and their receptors and how they are involved in angiogenesis and 
lymphangiogenesis. Only this can result in the discovery of new therapies. 
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